AMENDMENTS TO THE CLAIMS:

The listing of claims below will replace all prior versions and listing of claims in the above-identified application. Deleted matter is indicated by strikethrough or double brackets, and added matter is indicated by underlining.

1-13. (cancelled)

14. (currently amended) A propellant free buccal spray composition for transmucosal administration of a pharmacologically active compound soluble in a pharmacologically acceptable polar solvent comprising ~~in weight percent of the total composition:~~ a polar solvent in an amount ranging from 37-98.58% and an active compound in an amount ranging from 0.005-55% by weight of the total composition[[.]] ;

wherein the active compound is ~~selected from the group consisting of~~ comprises a central nervous system active ~~amines~~ amine, a sulfonyl ~~ureas~~ urea, ~~antibiotics~~ an antibiotic, ~~antifungals~~ an antifungal, ~~antivirals~~ an antiviral, a sleep ~~inducers~~ inducer, ~~antiasthmatics~~ an antiasthmatic, ~~antiemetics~~ an antiemetic, a histamine H-2 receptor ~~antagonists~~ antagonist, ~~barbiturates~~ a barbiturate, ~~prostoglandins~~ a prostoglandin~~, and~~ or a bronchial ~~dilators selected from the group consisting of~~ dilator comprising terbutaline ~~and~~ or theophyline.

15. (previously presented) The composition of claim 14, further comprising a flavoring agent in an amount ranging from 0.1 to 10 percent by weight of the composition.

16. (previously presented) The composition of claim 15, wherein the polar solvent is present in an amount ranging from 60.0 to 90.06 percent by weight of the composition, the active compound is present in an amount ranging from 0.01 to 40 percent by weight of the composition, and the flavoring agent is present in an amount ranging from 0.75 to 7.5 percent by weight of the composition

17. (currently amended) The ~~compoisition~~ composition of claim 14, wherein the polar solvent ~~is selected from the group consisting of~~ comprises a low molecular weight polyethylene ~~glycols~~ glycol (PEG) having a molecular weight ranging from 400 to 1,000, a C_2-C_8 mono- and ~~poly alcohols~~ polyalcohol~~, and alcohols~~ or an alcohol of C_7-C_{18} ~~hydrocarbons~~ hydrocarbon of linear or branched configuration.

18. (currently amended) The composition of claim 14, wherein the solvent ~~is~~ comprises aqueous polyethylene alcohol.

19. (currently amended) The composition of claim 14, wherein the solvent ~~is~~ comprises aqueous ethanol.

20. (currently amended) The composition of claim 14, wherein the active compound ~~is selected from the group consisting of~~ comprises cyclosporin, clozapine, zidevudine, erythromycin, ondansetron, cimetidine, phenytoin, carboprost thromethamine[[, and]] or valerian in ~~there~~ its non-ionized form or ~~as~~ a pharmaceutically acceptable ~~salts~~ salt thereof.

21. (previously presented) A method of administering a pharmacologically active compound to a mammal in need thereof, comprising spraying the oral mucosa of the mammal with the composition of claim 14.

22. (currently amended) The method of claim 21, wherein the amount of the spray ~~that is administered~~ is predetermined.